Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1

被引:30
|
作者
Vielhaber, Stefan
Jakubiczka, Sibylle
Gaul, Charly
Schoenfeld, Mircea Ariel
Debska-Vielhaber, Grazyna
Zierz, Stefan
Heinze, Hans-Jochen
Niessen, Heiko G.
Kaufmann, Joern
机构
[1] Univ Magdeburg, Dept Neurol 2, D-39120 Magdeburg, Germany
[2] Univ Magdeburg, Dept Human Genet, D-39120 Magdeburg, Germany
[3] Univ Halle Wittenberg, Dept Neurol, Halle, Germany
关键词
cerebral metabolites; H-1-MRS; myotonic dystrophy; N-acetylaspartate; spectroscopy;
D O I
10.1002/mus.20565
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To evaluate cerebral metabolism and intergroup differences in closely matched patients with myotonic dystrophy type 2 (DM2, n = 15) and type 1 (DM1, n = 14), we performed H-1 magnetic resonance spectroscopic (MRS) analyses of the occipital and temporoparietal cortical regions as well as of subcortical frontal white matter. Relative to healthy subjects, the concentration of N-acetylaspartate was significantly reduced in all tested brain regions in both disease groups. In the DM1 patients we also observed a concomitant depletion of creatine and choline levels, particularly in the frontal white matter. A discriminant analysis based on the H-1-MRS data distinguished between the DM2, DM1, and control groups with an overall accuracy of 88%. H-1-MRS indicates that neurochemical alterations involving gray and white matter occur in patients with DM2 and DM1. Although structural abnormalities (cerebral atrophy, white matter lesions) are similar in DM2 and DM1, changes in cerebral metabolites can differentiate these disease groups, suggesting that the diseases differ in their neurocellular pathology.
引用
收藏
页码:145 / 152
页数:8
相关论文
共 50 条
  • [21] Cardiac Pathology in Myotonic Dystrophy Type 1
    Mahadevan, Mani S.
    Yadava, Ramesh S.
    Mandal, Mahua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [22] Physical activity in myotonic dystrophy type 1
    Knak, Kirsten Lykke
    Sheikh, Aisha Munawar
    Witting, Nanna
    Vissing, John
    JOURNAL OF NEUROLOGY, 2020, 267 (06) : 1679 - 1686
  • [23] Life habits in myotonic dystrophy type 1
    Gagnon, Cynthia
    Mathieu, Jean
    Noreau, Luc
    JOURNAL OF REHABILITATION MEDICINE, 2007, 39 (07) : 560 - 566
  • [24] Disease burden of myotonic dystrophy type 1
    Erik Landfeldt
    Nikoletta Nikolenko
    Cecilia Jimenez-Moreno
    Sarah Cumming
    Darren G. Monckton
    Grainne Gorman
    Chris Turner
    Hanns Lochmüller
    Journal of Neurology, 2019, 266 : 998 - 1006
  • [25] Physical activity in myotonic dystrophy type 1
    Kirsten Lykke Knak
    Aisha Munawar Sheikh
    Nanna Witting
    John Vissing
    Journal of Neurology, 2020, 267 : 1679 - 1686
  • [26] THERAPEUTICS DEVELOPMENT IN MYOTONIC DYSTROPHY TYPE 1
    Foff, Erin Pennock
    Mahadevan, Mani S.
    MUSCLE & NERVE, 2011, 44 (02) : 160 - 169
  • [27] Oxidative stress in myotonic dystrophy type 1
    Toscano, A
    Messina, S
    Campo, GM
    Di Leo, R
    Musumeci, O
    Rodolico, C
    Aguennouz, M
    Annesi, G
    Messina, C
    Vita, G
    FREE RADICAL RESEARCH, 2005, 39 (07) : 771 - 776
  • [28] Targeting Myotonic Dystrophy Type 1 with Metformin
    Garcia-Puga, Mikel
    Saenz-Antonanzas, Ander
    Matheu, Ander
    Lopez de Munain, Adolfo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (05)
  • [29] Pathogenesis of myotonic dystrophy type 1.
    Magana, Jonathan J.
    Leyva-Garcia, Norberto
    Cisneros, Bulmaro
    GACETA MEDICA DE MEXICO, 2009, 145 (04): : 331 - 337
  • [30] Multiorgan manifestations in myotonic dystrophy type 1
    Varga David
    Pal Endre
    ORVOSI HETILAP, 2019, 160 (37) : 1447 - 1454